None listed
Conditions
Interventions
All subjects were randomised to receive either placebo or Acipimox capsules each week (two 250 mg capsules of the acute-bolus Aci therapy or placebo; 500 mg total - 5- Methylpyrazine-2-carboxylic acid 4-oxide, Olbetam capsules, Farmitalia Carlo Erba, Italy) 500 mg orally 1 hour before a single exercise bout, once a week over a total of 2 weeks. A low- to moderate-intensity exercise bout on an electromagnetically braked bicycle ergometer (Cateye EC 1600, Japan) was performed for 45 min at power o
All subjects were randomised to receive either placebo or Acipimox capsules each week (two 250 mg capsules of the acute-bolus Aci therapy or placebo; 500 mg total - 5- Methylpyrazine-2-carboxylic acid 4-oxide, Olbetam capsules, Farmitalia Carlo Erba, Italy) 500 mg orally 1 hour before a single exercise bout, once a week over a total of 2 weeks. A low- to moderate-intensity exercise bout on an electromagnetically braked bicycle ergometer (Cateye EC 1600, Japan) was performed for 45 min at power output 2 W/kg of lean body mass (LBM). All subjects during 45-min exercise were connected personally with their nurses and attending physicians.
Sponsors
Ministry of Health
Study design
Allocation
Randomised controlled trial
Primary purpose
Treatment
Eligibility
Sex/Gender
All
Age
18 Years to 30 Years
Healthy volunteers
Yes
Inclusion criteria
age between 18 and 30 years, BMI between 18 and 23 kg/m2, patients with a diagnosis of bulimia nervosa (Diagnostic and Statistical Manual of Mental Disorders, DSM-IV, 1994)
Exclusion criteria
hypertension, abnormal blood tests with significant hyperlipidaemia, history or presence of hepatic or renal disorders All eligible participants were deemed healthy.
Outcome results
None listed